CNAT Conatus Pharmaceuticals Inc.
0.38
0 -0%
Previous Close
0.38
Open
0.38
Price To Book
0.52
Market Cap
12,482,054
Shares
33,170,487
Volume
1,776,469
Short Ratio
Av. Daily Volume
765,029
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Phase 2b data June 24, 2019 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b trial did not meet primary endpoint - March 21, 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension